FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1600946808> ?p ?o ?g. }

• W1600946808 abstract "Currently the World Health Organization only recommend fluoroquinolones for people with presumed drug-sensitive tuberculosis (TB) who cannot take standard first-line drugs. However, use of fluoroquinolones could shorten the length of treatment and improve other outcomes in these people. This review summarises the effects of fluoroquinolones in first-line regimens in people with presumed drug-sensitive TB.To assess fluoroquinolones as substitute or additional components in antituberculous drug regimens for drug-sensitive TB.We searched the Cochrane Infectious Diseases Group Specialized Register; CENTRAL (The Cochrane Library 2013, Issue 1); MEDLINE; EMBASE; LILACS; Science Citation Index; Databases of Russian Publications; and metaRegister of Controlled Trials up to 6 March 2013.Randomized controlled trials (RCTs) of antituberculous regimens based on rifampicin and pyrazinamide and containing fluoroquinolones in people with presumed drug-sensitive pulmonary TB.Two authors independently applied inclusion criteria, assessed the risk of bias in the trials, and extracted data. We used the risk ratio (RR) for dichotomous data and the fixed-effect model when it was appropriate to combine data and no heterogeneity was present. We assessed the quality of evidence using the GRADE approach.We identified five RCTs (1330 participants) that met the inclusion criteria. None of the included trials examined regimens of less than six months duration. Fluoroquinolones added to standard regimensA single trial (174 participants) added levofloxacin to the standard first-line regimen. Relapse and treatment failure were not reported. For death, sputum conversion, and adverse events we are uncertain if there is an effect (one trial, 174 participants, very low quality evidence for all three outcomes). Fluoroquinolones substituted for ethambutol in standard regimens Three trials (723 participants) substituted ethambutol with moxifloxacin, gatifloxacin, and ofloxacin into the standard first-line regimen. For relapse, we are uncertain if there is an effect (one trial, 170 participants, very low quality evidence). No trials reported on treatment failure. For death, sputum culture conversion at eight weeks, or serious adverse events we do not know if there was an effect (three trials, 723 participants, very low quality evidence for all three outcomes). Fluoroquinolones substituted for isoniazid in standard regimens A single trial (433 participants) substituted moxifloxacin for isoniazid. Treatment failure and relapse were not reported. For death, sputum culture conversion, or serious adverse events the substitution may have little or no difference (one trial, 433 participants, low quality evidence for all three outcomes). Fluoroquinolines in four month regimensSix trials are currently in progress testing shorter regimens with fluoroquinolones.Ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin have been tested in RCTs of standard first-line regimens based on rifampicin and pyrazinamide for treating drug-sensitive TB. There is insufficient evidence to be clear whether addition or substitution of fluoroquinolones for ethambutol or isoniazid in the first-line regimen reduces death or relapse, or increases culture conversion at eight weeks. Much larger trials with fluoroquinolones in short course regimens of four months are currently in progress." @default.
• W1600946808 created "2016-06-24" @default.
• W1600946808 creator A5013868193 @default.
• W1600946808 creator A5020420402 @default.
• W1600946808 creator A5085271816 @default.
• W1600946808 date "2013-06-06" @default.
• W1600946808 modified "2023-10-12" @default.
• W1600946808 title "Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)" @default.
• W1600946808 cites W134021677 @default.
• W1600946808 cites W13459688 @default.
• W1600946808 cites W1582480227 @default.
• W1600946808 cites W1920771564 @default.
• W1600946808 cites W1965009420 @default.
• W1600946808 cites W1965877207 @default.
• W1600946808 cites W1966126698 @default.
• W1600946808 cites W1966820980 @default.
• W1600946808 cites W1967748659 @default.
• W1600946808 cites W1973110906 @default.
• W1600946808 cites W1975866794 @default.
• W1600946808 cites W1986822335 @default.
• W1600946808 cites W1996896990 @default.
• W1600946808 cites W1996930122 @default.
• W1600946808 cites W2013369772 @default.
• W1600946808 cites W2019023077 @default.
• W1600946808 cites W2028372167 @default.
• W1600946808 cites W203154064 @default.
• W1600946808 cites W2032353669 @default.
• W1600946808 cites W2034077454 @default.
• W1600946808 cites W2045865641 @default.
• W1600946808 cites W2047505716 @default.
• W1600946808 cites W2047606924 @default.
• W1600946808 cites W205622831 @default.
• W1600946808 cites W2061088592 @default.
• W1600946808 cites W2065376976 @default.
• W1600946808 cites W2076991882 @default.
• W1600946808 cites W2079152792 @default.
• W1600946808 cites W2080750733 @default.
• W1600946808 cites W2095037435 @default.
• W1600946808 cites W2095281873 @default.
• W1600946808 cites W2095544141 @default.
• W1600946808 cites W2098793988 @default.
• W1600946808 cites W2102212813 @default.
• W1600946808 cites W2105465792 @default.
• W1600946808 cites W2107201851 @default.
• W1600946808 cites W2108206593 @default.
• W1600946808 cites W2112915624 @default.
• W1600946808 cites W2118660489 @default.
• W1600946808 cites W2122862490 @default.
• W1600946808 cites W2124584779 @default.
• W1600946808 cites W2128655608 @default.
• W1600946808 cites W2129047823 @default.
• W1600946808 cites W2131178604 @default.
• W1600946808 cites W2134527984 @default.
• W1600946808 cites W2135027892 @default.
• W1600946808 cites W2135989318 @default.
• W1600946808 cites W2141060790 @default.
• W1600946808 cites W2143521921 @default.
• W1600946808 cites W2144010669 @default.
• W1600946808 cites W2148205948 @default.
• W1600946808 cites W2149860604 @default.
• W1600946808 cites W2152518626 @default.
• W1600946808 cites W2153938082 @default.
• W1600946808 cites W2155336089 @default.
• W1600946808 cites W2155742575 @default.
• W1600946808 cites W2158263022 @default.
• W1600946808 cites W2158658436 @default.
• W1600946808 cites W2159470927 @default.
• W1600946808 cites W2162098313 @default.
• W1600946808 cites W2164918529 @default.
• W1600946808 cites W2165010366 @default.
• W1600946808 cites W2337631827 @default.
• W1600946808 cites W2387794311 @default.
• W1600946808 cites W2408658112 @default.
• W1600946808 cites W2411067771 @default.
• W1600946808 cites W2413118643 @default.
• W1600946808 cites W2414057563 @default.
• W1600946808 cites W2414689530 @default.
• W1600946808 cites W2418210342 @default.
• W1600946808 cites W2418872045 @default.
• W1600946808 cites W2425544933 @default.
• W1600946808 cites W2435587869 @default.
• W1600946808 cites W2441223914 @default.
• W1600946808 cites W2469145797 @default.
• W1600946808 cites W2803641 @default.
• W1600946808 cites W4232723310 @default.
• W1600946808 cites W4238748109 @default.
• W1600946808 cites W4240592900 @default.
• W1600946808 cites W4243233769 @default.
• W1600946808 cites W4298241987 @default.
• W1600946808 cites W6296198 @default.
• W1600946808 cites W68650690 @default.
• W1600946808 cites W83645377 @default.
• W1600946808 cites W89947807 @default.
• W1600946808 cites W94421562 @default.
• W1600946808 doi "https://doi.org/10.1002/14651858.cd004795.pub4" @default.
• W1600946808 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6532730" @default.
• W1600946808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23744519" @default.
• W1600946808 hasPublicationYear "2013" @default.
• W1600946808 type Work @default.
• W1600946808 sameAs 1600946808 @default.

• next